Skip to Content
Merck

DNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity.

Nucleic acid therapeutics (2015-07-21)
Liang Xu, Tao Zhang, Xiaoyu Xu, Huihui Chong, Wenqing Lai, Xifeng Jiang, Chao Wang, Yuxian He, Keliang Liu
ABSTRACT

DNA triplexes with hydrophobic modifications were designed and evaluated for their activity as inhibitors of the cell fusion of human immunodeficiency virus type 1 (HIV-1). Triplex inhibitors displayed low micromolar activities in the cell-cell fusion assay and nanomolar activities in the anti-HIV-1 pseudovirus test. Helix structure and the presence of sufficient numbers of hydrophobic regions were essential for the antifusion activity. Results from native polyacrylamide gel electrophoresis and a fluorescent resonance energy transfer-based inhibitory assay indicated that these triplexes may interact with the primary pocket at the glycoprotein 41 (gp41) N-heptad repeat, thereby inhibiting formation of the HIV-1 gp41 6-helical bundle. Triplex-based complexes may represent a novel category of HIV-1 inhibitors in anti-HIV-1 drug discovery.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2′,4′,6′-Trihydroxyacetophenone monohydrate, 98%